• Organizations: LumiThera
LumiThera Valeda system extension trial data expands dry AMD vision improvements
Research

LumiThera Valeda system extension trial data expands dry AMD vision improvements

Presented at ARVO, new findings support earlier initiation and extended vision benefits of Valeda Light Delivery System out to 4.5 years.
FDA grants authorization to LumiThera's Valeda system for dry AMD
Products

FDA grants authorization to LumiThera's Valeda system for dry AMD

Approval makes the photobiomodulation treatment the first device of its kind to treat vision loss among dry AMD patients.
LumiThera receives first CPT code for retina-based PBM therapy
Legal

LumiThera receives first CPT code for retina-based PBM therapy

New Category III code applies to the Valeda Light Delivery System, intended to treat dry AMD.
LumiThera submits FDA De Novo request for Valeda Light Delivery System
Pipeline

LumiThera submits FDA De Novo request for Valeda Light Delivery System

Pending potential acceptance, the photobiomodulation treatment system could be introduced into the U.S. market by mid-2024.
LumiThera receives NIH grant for dry AMD extension trial
Research

LumiThera receives NIH grant for dry AMD extension trial

Funding will support an additional year of open-label study for LIGHTSITE III.
LumiThera reports 24-month data from LIGHTSITE III trial for dry AMD
Pipeline

LumiThera reports 24-month data from LIGHTSITE III trial for dry AMD

Following initial data, latest results support the use of the Valeda Light Delivery System.